Skip to main content
Premium Trial:

Request an Annual Quote

Fisher and Nanogen Will Share IP, Technologies to Co-Develop Molecular Dxs

NEW YORK (GenomeWeb News) – Nanogen and Fisher Scientific International today said they will share each other's technology and patent rights in order to develop, manufacture, and market new molecular diagnostic products.
As part of the deal, which complements Fisher's equity investment in Nanogen in March, Fisher “may provide” Nanogen up to $10 million during 2007 and 2008 to research and develop infectious disease and molecular diagnostic tests “that will be mutually agreed upon.”
Additionally, Nanogen and Fisher’s Athena Diagnostics subsidiary plan to manufacture and market products based on Athena's biomarkers for research and for in vitro diagnostic use.
Athena has markers in neurology and endocrinology that it has incorporated into its testing service, several of which could be incorporated into assays for use on Nanogen's NanoChip400 microarray platform, Fisher and Nanogen said.
“Likewise,” Nanogen has access to a “wide range of markers” that could be used to create tests for the Athena Diagnostics testing service.
Additional details were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.